Of these non-JAK2 mutation cases, the NRAS, CSF3R and TET2 c.4319_4329del; p.Arg1440Hisfs*34 were in the context of therapy-related disease; the remaining 4 other mutations (TET2, TET2, DNMT3A, and SF3B1) were in the context of disease progression from myelodysplastic syndrome. This evidence concerns the gene DNMT3A and myelodysplastic syndrome.